Citigroup Upgrades Larimar Therapeutics to Buy, Announces $4.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Samantha Semenkow has upgraded Larimar Therapeutics (NASDAQ:LRMR) from Neutral to Buy and set a price target of $4.5.

November 17, 2023 | 9:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Larimar Therapeutics was upgraded by Citigroup from Neutral to Buy with a new price target of $4.5.
Analyst upgrades typically lead to a positive short-term reaction in the stock price as they suggest improved prospects for the company. The new price target of $4.5 indicates a potential upside from the current trading price, which can attract investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100